社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Alumis Inc.(ALMS)
盘后
21.62
-0.49
-2.20%
16:07 EST
22.11
+1.02
+4.84%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
牛唐
·
2025-04-14
美股暴跌之下：这家药企为何十天逆势上涨三倍？
3月25日至4月5日，美股纳斯达克指数下跌14.35%，生物医药指数（美国生科ETF-SPDR(ARCA:XBI)）下跌17.17%。 同期，美股上市的Biotech公司Alumis(NASDAQ:ALMS)却从3.18美元涨至10.05美元，涨幅近3倍，一家小市值生物医药企业为何逆势上涨？ 图片 核心资产来自中国的，融资超7亿美元的Biotech Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。 目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。 2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。 ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。 Alumis在2025年美国皮肤病学会协会（AAD）年会上公布了ESK-001名为STRIDE临床二期试验开放标签扩展研究（OLE）的最新数据。这项长达52周的数据进一步证实了ESK-001在治疗中重度斑块状银屑病患者中的显著且持续的临床疗效以及良好的安全性。 目前，ESK-001正在进行3期ONWARD临床项目的评估，该项目包括两项平行的全球性、多中心、随机、双盲、安慰剂对照的24周临床试验ONWARD1和ONWARD2，旨在评估ESK-001在成人中重度斑块状银屑病患者中的疗效和安全性，预计将在2026年第一季度获得关键的top line数据。除了银屑病，ESK-001还在一项名为
美股暴跌之下：这家药企为何十天逆势上涨三倍？
精彩
尖沙咀啵嘴:
担心药股也会收到关税影响啊
回复
2
点赞
3
编组 21备份 2
分享
举报
牛唐
·
2024-07-01
核心资产来自中国，累计融资超7亿美元的药企完成上市
6月28日，Alumis(NASDAQ:ALMS)在美国纳斯达克交易所上市，发行价为每股16美元，发行1312.5万股，IPO规模达2.1亿美元，是今年以来，IPO发行规模第三大的生物医药公司。 图片 核心资产来自中国，累计融资超7亿美元 Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。 目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。 2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。 ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。 ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。在不久前发布的治疗中重度斑块状银屑病的临床二期STRIDE试验中，ESK001的数据优异： 有效性方面，228例银屑病患者随机接受5种剂量ESK-001或安慰剂治疗12周后，治疗组均达到了PASI 75的主要终点与关键的次要疗效终点，并且展现出明显的剂量依赖性； 安全性方面，治疗组没有出现与治疗相关的严重不良事件，AE发生率与安慰剂组相近。 Alumis计划在2024年下半年推进ESK-001用于治疗中重度斑块状银屑病的3期试验，同时开展两项治疗系统性红斑狼疮和非传染性葡萄膜炎的2期临床试验。随着今年下半年ESK-001的三期临床启动，海思科预计将收到第二个里程碑付款（约1284.32万美元）。 Alumis的另一款药物A-005是一种中枢神经系统渗透性变构TYK2抑制剂，用于治疗神经炎症和神经
核心资产来自中国，累计融资超7亿美元的药企完成上市
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
牛唐
·
2024-07-01
核心资产来自中国，累计融资超7亿美元的药企完成上市
6月28日，Alumis(NASDAQ:ALMS)在美国纳斯达克交易所上市，发行价为每股16美元，发行1312.5万股，IPO规模达2.1亿美元，是今年以来，IPO发行规模第三大的生物医药公司。核心资产来自中国，累计融资超7亿美元Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。在不久前发布的治疗中重度斑块状银屑病的临床二期STRIDE试验中，ESK001的数据优异：有效性方面，228例银屑病患者随机接受5种剂量ESK-001或安慰剂治疗12周后，治疗组均达到了PASI 75的主要终点与关键的次要疗效终点，并且展现出明显的剂量依赖性；安全性方面，治疗组没有出现与治疗相关的严重不良事件，AE发生率与安慰剂组相近。Alumis计划在2024年下半年推进ESK-001用于治疗中重度斑块状银屑病的3期试验，同时开展两项治疗系统性红斑狼疮和非传染性葡萄膜炎的2期临床试验。随着今年下半年ESK-001的三期临床启动，海思科预计将收到第二个里程碑付款（约1284.32万美元）。Alumis的另一款药物A-005是一种中枢神经系统渗透性变构TYK2抑制剂，用于治疗神经炎症和神经退行性疾病，2024年4月
核心资产来自中国，累计融资超7亿美元的药企完成上市
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
美股之家
·
2024-06-25
本周美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)
本周（2024.6.24-6.28）截止目前可能IPO上市的公司共计12家，其中8家确定性较高，其中比较值得关注的包括WEBTOON(WBTN)、LandBridge(LB)和Alumis Inc.(ALMS)，下面为大家一一介绍。一、周三（6/26/2024）上市新股1、中国医疗产品制造商 – 沃克医疗 WORK Medical Technology Group(WOK)本周（2024.6.24-6.28）美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)沃克医疗科技集团（杭州山友医疗器械有限公司）WORK Medical Technology Group(NASDAQ:WOK)创立于2002年，总部位于中国杭州，全职雇员216人，是一家专业生产麻醉、呼吸、急救、ICU、介入、口罩等医疗消耗品的企业，先后引进国内外先进的塑料注塑、挤塑成形、包装封口等专业设备。沃克医疗公司最新计划以 4 至 5 美元的价格发行 200 万股股票，筹集 900 万美元，筹集的资金将比之前预期的少 33%。 Univest Securities 独家承销。2、希腊国际航运公司 – Icon Energy Corp.(ICON)本周（2024.6.24-6.28）美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)Icon Energy Corp.(NASDAQ:ICON)
$Icon Energy Corp.(ICON)$
创立于2023年，总部位于希腊雅典，是一家国际航运公司，最近在马绍尔群岛共和国注册成立，旨在收购、拥有、租赁和运营干散货船。Icon Energy Corp.计划于2024年6月26日IPO上市登录纳斯达克，发行价$4.00 – $6.00，发行130万股，募资63
本周美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
Alumis Inc.
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.alumis.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Alumis Inc.于2021年1月29日注册成立，为特拉华州公司。他们是一家临床阶段的生物制药公司，最初专注于开发两种酪氨酸激酶2（TYK2）抑制剂：ESK-001，一种他们正在开发的第二代抑制剂，以实现最大的靶向抑制，以及A-005，一种中枢神经系统渗透分子。该公司的使命是通过靶向治疗取代广泛的免疫抑制，显著改善患者的生活。
01-09
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-06
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-02
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-11-13
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025-11-13
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-09-03
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-08-16
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
2025-08-13
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025-08-13
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-08-04
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-06-30
重要事件披露
Form 8-K/A - Current report: [Amend]
Form 8-K/A - Current report: [Amend]
2025-06-10
员工持股计划
Form S-8 - Securities to be offered to employees in employee benefit plans
Form S-8 - Securities to be offered to employees in employee benefit plans
2025-05-21
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-05-20
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-05-15
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
分时
5日
日
周
月
数据加载中...
最高
23.00
今开
20.85
量比
0.25
最低
20.20
昨收
21.09
换手率
6.01%
热议股票
{"pagemeta":{"title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"ALMS","data":{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":22.11,"timestamp":1768338000000,"preClose":21.09,"halted":0,"volume":4657074,"hourTrading":{"tag":"盘后","latestPrice":21.6235,"preClose":22.11,"latestTime":"16:07 EST","volume":15885,"amount":350874.26577,"timestamp":1768338443872},"delay":0,"floatShares":77486300,"shares":122000000,"eps":-3.8545,"marketStatus":"盘后交易","change":1.02,"latestTime":"01-13 16:07:26 EST","open":20.85,"high":23,"low":20.2,"amount":102008935.433142,"amplitude":0.132764,"askPrice":22.5,"askSize":100,"bidPrice":21.55,"bidSize":250,"shortable":3,"etf":0,"ttmEps":-3.8545,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768352400000},"marketStatusCode":4,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":21.09,"preHourTrading":{"tag":"盘前","latestPrice":21.01,"preClose":21.09,"latestTime":"09:29 EST","volume":62367,"amount":1328447.160894,"timestamp":1768314578807},"postHourTrading":{"tag":"盘后","latestPrice":21.6235,"preClose":22.11,"latestTime":"16:07 EST","volume":15885,"amount":350874.26577,"timestamp":1768338443872},"volumeRatio":0.246115,"impliedVol":1.1873,"impliedVolPercentile":0.3438},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.424238125814024","cardData":[{"tweetId":"424238125814024","author":{"authorId":"3452938437060827","idStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6593,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"美股暴跌之下：这家药企为何十天逆势上涨三倍？","digest":"3月25日至4月5日，美股纳斯达克指数下跌14.35%，生物医药指数（美国生科ETF-SPDR(ARCA:XBI)）下跌17.17%。 同期，美股上市的Biotech公司Alumis(NASDAQ:ALMS)却从3.18美元涨至10.05美元，涨幅近3倍，一家小市值生物医药企业为何逆势上涨？ 图片 核心资产来自中国的，融资超7亿美元的Biotech Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。 目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。 2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。 ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。 Alumis在2025年美国皮肤病学会协会（AAD）年会上公布了ESK-001名为STRIDE临床二期试验开放标签扩展研究（OLE）的最新数据。这项长达52周的数据进一步证实了ESK-001在治疗中重度斑块状银屑病患者中的显著且持续的临床疗效以及良好的安全性。 目前，ESK-001正在进行3期ONWARD临床项目的评估，该项目包括两项平行的全球性、多中心、随机、双盲、安慰剂对照的24周临床试验ONWARD1和ONWARD2，旨在评估ESK-001在成人中重度斑块状银屑病患者中的疗效和安全性，预计将在2026年第一季度获得关键的top line数据。除了银屑病，ESK-001还在一项名为","plainDigest":"3月25日至4月5日，美股纳斯达克指数下跌14.35%，生物医药指数（美国生科ETF-SPDR(ARCA:XBI)）下跌17.17%。 同期，美股上市的Biotech公司Alumis(NASDAQ:ALMS)却从3.18美元涨至10.05美元，涨幅近3倍，一家小市值生物医药企业为何逆势上涨？ 图片 核心资产来自中国的，融资超7亿美元的Biotech Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。 目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。 2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。 ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。 Alumis在2025年美国皮肤病学会协会（AAD）年会上公布了ESK-001名为STRIDE临床二期试验开放标签扩展研究（OLE）的最新数据。这项长达52周的数据进一步证实了ESK-001在治疗中重度斑块状银屑病患者中的显著且持续的临床疗效以及良好的安全性。 目前，ESK-001正在进行3期ONWARD临床项目的评估，该项目包括两项平行的全球性、多中心、随机、双盲、安慰剂对照的24周临床试验ONWARD1和ONWARD2，旨在评估ESK-001在成人中重度斑块状银屑病患者中的疗效和安全性，预计将在2026年第一季度获得关键的top line数据。除了银屑病，ESK-001还在一项名为","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1744592646447,"gmtModify":1744904482806,"symbols":["ONC","NVO","LLY","ALMS","XBI","688235","06160"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":3,"images":[{"url":"https://static.tigerbbs.com/168d0d77c5af52acd4f651f61e3910ee","width":"687","height":"678"},{"url":"https://static.tigerbbs.com/9c60312a66e7f74e017a278893465b2b","width":"1080","height":"372"},{"url":"https://static.tigerbbs.com/fedd4ef4a2b52311acd96c899470e07c","width":"1044","height":"799"}],"repostCount":0,"viewCount":10228,"likeCount":3,"liked":false,"collected":false,"commentCount":2,"hotComments":[{"id":"424266923167752","author":{"authorId":"4142416961445330","idStr":"4142416961445330","name":"尖沙咀啵嘴","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"fanSize":315,"starInvestorFlag":false},"content":"担心药股也会收到关税影响啊","plainContent":"担心药股也会收到关税影响啊","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/424238125814024","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":5430,"displayRows":4,"foldSize":0,"authorId":"3452938437060827"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.322705100308592","cardData":[{"tweetId":"322705100308592","author":{"authorId":"3452938437060827","idStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6593,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"核心资产来自中国，累计融资超7亿美元的药企完成上市","digest":"6月28日，Alumis(NASDAQ:ALMS)在美国纳斯达克交易所上市，发行价为每股16美元，发行1312.5万股，IPO规模达2.1亿美元，是今年以来，IPO发行规模第三大的生物医药公司。 图片 核心资产来自中国，累计融资超7亿美元 Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。 目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。 2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。 ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。 ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。在不久前发布的治疗中重度斑块状银屑病的临床二期STRIDE试验中，ESK001的数据优异： 有效性方面，228例银屑病患者随机接受5种剂量ESK-001或安慰剂治疗12周后，治疗组均达到了PASI 75的主要终点与关键的次要疗效终点，并且展现出明显的剂量依赖性； 安全性方面，治疗组没有出现与治疗相关的严重不良事件，AE发生率与安慰剂组相近。 Alumis计划在2024年下半年推进ESK-001用于治疗中重度斑块状银屑病的3期试验，同时开展两项治疗系统性红斑狼疮和非传染性葡萄膜炎的2期临床试验。随着今年下半年ESK-001的三期临床启动，海思科预计将收到第二个里程碑付款（约1284.32万美元）。 Alumis的另一款药物A-005是一种中枢神经系统渗透性变构TYK2抑制剂，用于治疗神经炎症和神经","plainDigest":"6月28日，Alumis(NASDAQ:ALMS)在美国纳斯达克交易所上市，发行价为每股16美元，发行1312.5万股，IPO规模达2.1亿美元，是今年以来，IPO发行规模第三大的生物医药公司。 图片 核心资产来自中国，累计融资超7亿美元 Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。 目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。 2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。 ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。 ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。在不久前发布的治疗中重度斑块状银屑病的临床二期STRIDE试验中，ESK001的数据优异： 有效性方面，228例银屑病患者随机接受5种剂量ESK-001或安慰剂治疗12周后，治疗组均达到了PASI 75的主要终点与关键的次要疗效终点，并且展现出明显的剂量依赖性； 安全性方面，治疗组没有出现与治疗相关的严重不良事件，AE发生率与安慰剂组相近。 Alumis计划在2024年下半年推进ESK-001用于治疗中重度斑块状银屑病的3期试验，同时开展两项治疗系统性红斑狼疮和非传染性葡萄膜炎的2期临床试验。随着今年下半年ESK-001的三期临床启动，海思科预计将收到第二个里程碑付款（约1284.32万美元）。 Alumis的另一款药物A-005是一种中枢神经系统渗透性变构TYK2抑制剂，用于治疗神经炎症和神经","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1719794437540,"gmtModify":1719794460553,"symbols":["BGNE","ZLAB","LEGN","ALMS","XBI","09688","688235","06160"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":2,"images":[{"url":"https://static.tigerbbs.com/764dbb9b86f6fd274aab045c6f6848d2","width":"688","height":"712"}],"repostCount":0,"viewCount":4085,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/322705100308592","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3866,"displayRows":4,"foldSize":0,"authorId":"3452938437060827"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.323170202853656","cardData":[{"tweetId":"323170202853656","author":{"authorId":"3452938437060827","idStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6593,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"核心资产来自中国，累计融资超7亿美元的药企完成上市","digest":"6月28日，Alumis(NASDAQ:ALMS)在美国纳斯达克交易所上市，发行价为每股16美元，发行1312.5万股，IPO规模达2.1亿美元，是今年以来，IPO发行规模第三大的生物医药公司。核心资产来自中国，累计融资超7亿美元Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。在不久前发布的治疗中重度斑块状银屑病的临床二期STRIDE试验中，ESK001的数据优异：有效性方面，228例银屑病患者随机接受5种剂量ESK-001或安慰剂治疗12周后，治疗组均达到了PASI 75的主要终点与关键的次要疗效终点，并且展现出明显的剂量依赖性；安全性方面，治疗组没有出现与治疗相关的严重不良事件，AE发生率与安慰剂组相近。Alumis计划在2024年下半年推进ESK-001用于治疗中重度斑块状银屑病的3期试验，同时开展两项治疗系统性红斑狼疮和非传染性葡萄膜炎的2期临床试验。随着今年下半年ESK-001的三期临床启动，海思科预计将收到第二个里程碑付款（约1284.32万美元）。Alumis的另一款药物A-005是一种中枢神经系统渗透性变构TYK2抑制剂，用于治疗神经炎症和神经退行性疾病，2024年4月","plainDigest":"6月28日，Alumis(NASDAQ:ALMS)在美国纳斯达克交易所上市，发行价为每股16美元，发行1312.5万股，IPO规模达2.1亿美元，是今年以来，IPO发行规模第三大的生物医药公司。核心资产来自中国，累计融资超7亿美元Alumis成立于2021年，由Foresite Capital旗下的Forsite Labs孵化设立，是一家专注于TYK2抑制剂在自体免疫性疾病领域运用的生物医药公司。目前，Alumis有两款在研药物，其中进度最快的是ESK-001。该药物源自海思科旗下的子公司FT集团。2021年，FT集团以6000万美元首付款，以及1.2亿美元里程碑的价格将TYK2项目转让给FL2021-001公司（Alumis的前身）。ESK-001是一款高选择性且有Best-in-Class潜力的TYK2抑制剂，研发进度处于全球第三，仅次于BMS和武田。ESK-001在其选择性、优化的分子性质/药代动力学、最大化靶点抑制效应、更好的耐受性等方面均具有差异化的优势。在不久前发布的治疗中重度斑块状银屑病的临床二期STRIDE试验中，ESK001的数据优异：有效性方面，228例银屑病患者随机接受5种剂量ESK-001或安慰剂治疗12周后，治疗组均达到了PASI 75的主要终点与关键的次要疗效终点，并且展现出明显的剂量依赖性；安全性方面，治疗组没有出现与治疗相关的严重不良事件，AE发生率与安慰剂组相近。Alumis计划在2024年下半年推进ESK-001用于治疗中重度斑块状银屑病的3期试验，同时开展两项治疗系统性红斑狼疮和非传染性葡萄膜炎的2期临床试验。随着今年下半年ESK-001的三期临床启动，海思科预计将收到第二个里程碑付款（约1284.32万美元）。Alumis的另一款药物A-005是一种中枢神经系统渗透性变构TYK2抑制剂，用于治疗神经炎症和神经退行性疾病，2024年4月","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1719788400000,"gmtModify":1719926626076,"symbols":["SLE","ALMS"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":2,"images":[{"url":"https://static.tigerbbs.com/22425dc967dc4fb8bf6daad875f8b431"}],"repostCount":0,"viewCount":3797,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/323170202853656","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3768,"displayRows":4,"foldSize":0,"authorId":"3452938437060827"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.320496236998800","cardData":[{"tweetId":"320496236998800","author":{"authorId":"10790722010898","idStr":"10790722010898","name":"美股之家","avatar":"https://static.tigerbbs.com/4a72f7d16c06b759c1ceb59ddc3be2d8","userType":6,"introduction":"美股之家（www.mg21.com），专注美股投资","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8765,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"本周美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)","digest":"本周（2024.6.24-6.28）截止目前可能IPO上市的公司共计12家，其中8家确定性较高，其中比较值得关注的包括WEBTOON(WBTN)、LandBridge(LB)和Alumis Inc.(ALMS)，下面为大家一一介绍。一、周三（6/26/2024）上市新股1、中国医疗产品制造商 – 沃克医疗 WORK Medical Technology Group(WOK)本周（2024.6.24-6.28）美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)沃克医疗科技集团（杭州山友医疗器械有限公司）WORK Medical Technology Group(NASDAQ:WOK)创立于2002年，总部位于中国杭州，全职雇员216人，是一家专业生产麻醉、呼吸、急救、ICU、介入、口罩等医疗消耗品的企业，先后引进国内外先进的塑料注塑、挤塑成形、包装封口等专业设备。沃克医疗公司最新计划以 4 至 5 美元的价格发行 200 万股股票，筹集 900 万美元，筹集的资金将比之前预期的少 33%。 Univest Securities 独家承销。2、希腊国际航运公司 – Icon Energy Corp.(ICON)本周（2024.6.24-6.28）美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)Icon Energy Corp.(NASDAQ:ICON) <a href=\"https://laohu8.com/S/ICON\">$Icon Energy Corp.(ICON)$</a> 创立于2023年，总部位于希腊雅典，是一家国际航运公司，最近在马绍尔群岛共和国注册成立，旨在收购、拥有、租赁和运营干散货船。Icon Energy Corp.计划于2024年6月26日IPO上市登录纳斯达克，发行价$4.00 – $6.00，发行130万股，募资63","plainDigest":"本周（2024.6.24-6.28）截止目前可能IPO上市的公司共计12家，其中8家确定性较高，其中比较值得关注的包括WEBTOON(WBTN)、LandBridge(LB)和Alumis Inc.(ALMS)，下面为大家一一介绍。一、周三（6/26/2024）上市新股1、中国医疗产品制造商 – 沃克医疗 WORK Medical Technology Group(WOK)本周（2024.6.24-6.28）美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)沃克医疗科技集团（杭州山友医疗器械有限公司）WORK Medical Technology Group(NASDAQ:WOK)创立于2002年，总部位于中国杭州，全职雇员216人，是一家专业生产麻醉、呼吸、急救、ICU、介入、口罩等医疗消耗品的企业，先后引进国内外先进的塑料注塑、挤塑成形、包装封口等专业设备。沃克医疗公司最新计划以 4 至 5 美元的价格发行 200 万股股票，筹集 900 万美元，筹集的资金将比之前预期的少 33%。 Univest Securities 独家承销。2、希腊国际航运公司 – Icon Energy Corp.(ICON)本周（2024.6.24-6.28）美股IPO预告：12家公司可能上市，关注WEBTOON(WBTN)Icon Energy Corp.(NASDAQ:ICON) $Icon Energy Corp.(ICON)$ 创立于2023年，总部位于希腊雅典，是一家国际航运公司，最近在马绍尔群岛共和国注册成立，旨在收购、拥有、租赁和运营干散货船。Icon Energy Corp.计划于2024年6月26日IPO上市登录纳斯达克，发行价$4.00 – $6.00，发行130万股，募资63","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1719279031701,"gmtModify":1719296513730,"symbols":["LSH","ICON","WBTN","LB","ALMS"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":7,"images":[{"url":"https://static.tigerbbs.com/770c52016989fad104b5200035fbf775","width":"600","height":"450"},{"url":"https://static.tigerbbs.com/c5987abbe7606db77bcd0e9a5d67b73a","width":"579","height":"427"},{"url":"https://static.tigerbbs.com/0bd2d3eff41f6eb9d9e63c60b2576bff","width":"800","height":"600"}],"repostCount":0,"viewCount":7685,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/320496236998800","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4031,"displayRows":4,"foldSize":0,"authorId":"10790722010898"}],"position":0}],"size":4},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20619068","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465926002265-ALMS","pdf_url":"","pub_time":1767934800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926002265/0001104659-26-002265-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 1.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926002265/tm262561d1_ex1-1.htm","primary":true,"translateUrl":"","linkName":"tm262561d1_ex1-1.htm","type":"EX-1.1","id":"NTFILE2vMrRXCCnPEFDEnf","market":"us","size":196165},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926002265/tm262561d1_8k.htm","primary":false,"translateUrl":"","linkName":"tm262561d1_8k.htm","type":"8-K","id":"NTFILE4RhgPRLAuNF9ieCU","market":"us","size":34582},{"description":"EXHIBIT 5.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926002265/tm262561d1_ex5-1.htm","primary":false,"translateUrl":"","linkName":"tm262561d1_ex5-1.htm","type":"EX-5.1","id":"NTFILE3a9MRG3kW3HMzFMm","market":"us","size":11153},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926002265/tm262561d1_ex5-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm262561d1_ex5-1img001.jpg","type":"GRAPHIC","id":"NTFILE7JPF64eFf9nZkCwY","market":"us","size":2857},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926002265/tm262561d1_ex5-1img002.jpg","primary":false,"translateUrl":"","linkName":"tm262561d1_ex5-1img002.jpg","type":"GRAPHIC","id":"NTFILEBVT2sK6N192roWp7","market":"us","size":2822}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-09 13:00","pubTimestamp":1767934800,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目2.02：经营业绩和财务状况；项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20606812","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465926001073-ALMS","pdf_url":"","pub_time":1767675600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/0001104659-26-001073-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm","primary":true,"translateUrl":"","linkName":"tm262035d1_ex99-1.htm","type":"EX-99.1","id":"NTFILECDESEojwDvWJWkEc","market":"us","size":19172},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_8k.htm","primary":false,"translateUrl":"","linkName":"tm262035d1_8k.htm","type":"8-K","id":"NTFILE75kawnDAB76Fwnw8","market":"us","size":30443},{"description":"EXHIBIT 99.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2.htm","type":"EX-99.2","id":"NTFILE84NR3GGVq7bWmQLe","market":"us","size":36427},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img01.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img01.jpg","type":"GRAPHIC","id":"NTFILEFSgQTJE9qGdGWKbU","market":"us","size":589467},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img02.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img02.jpg","type":"GRAPHIC","id":"NTFILEF9MLRyDzbphZ9k1e","market":"us","size":770184},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img03.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img03.jpg","type":"GRAPHIC","id":"NTFILE2L7cuU72F28zcuku","market":"us","size":210831},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img04.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img04.jpg","type":"GRAPHIC","id":"NTFILEG9mnELd87hpKCaWD","market":"us","size":216912},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img05.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img05.jpg","type":"GRAPHIC","id":"NTFILE92dsQHiYMWp7vZ3f","market":"us","size":437917},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img06.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img06.jpg","type":"GRAPHIC","id":"NTFILE9SrDmx5J5xrcUrN9","market":"us","size":482240},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img07.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img07.jpg","type":"GRAPHIC","id":"NTFILE2KUJsGLP5CDete62","market":"us","size":434445},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img08.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img08.jpg","type":"GRAPHIC","id":"NTFILE7pDSjGnvojhmFL76","market":"us","size":440404},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img09.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img09.jpg","type":"GRAPHIC","id":"NTFILEHhY2BCCBirvEHCdY","market":"us","size":243074},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img10.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img10.jpg","type":"GRAPHIC","id":"NTFILEBDfbuZ5bKpd8gTCn","market":"us","size":414025},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img11.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img11.jpg","type":"GRAPHIC","id":"NTFILE7zuxtxj7L94FKuGe","market":"us","size":401707},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img12.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img12.jpg","type":"GRAPHIC","id":"NTFILEHxJ8hmroocbZchhf","market":"us","size":358623},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img13.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img13.jpg","type":"GRAPHIC","id":"NTFILEEsKrJRFUm6HivTNT","market":"us","size":448247},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img14.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img14.jpg","type":"GRAPHIC","id":"NTFILEF9PUfff3LqBK3Sai","market":"us","size":442975},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img15.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img15.jpg","type":"GRAPHIC","id":"NTFILE38dwwf1dECvEkz4m","market":"us","size":379621},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img16.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img16.jpg","type":"GRAPHIC","id":"NTFILE81LXXvLMGzWdWKVt","market":"us","size":373886},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img17.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img17.jpg","type":"GRAPHIC","id":"NTFILEEkFYeywKyo8goLwF","market":"us","size":349901},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img18.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img18.jpg","type":"GRAPHIC","id":"NTFILEFaze5WYs8RiTbkAm","market":"us","size":239461},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img19.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img19.jpg","type":"GRAPHIC","id":"NTFILEBCQqDRCqt5CqJBdo","market":"us","size":566815},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img20.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img20.jpg","type":"GRAPHIC","id":"NTFILEGQbMZPyzCUsdP7gQ","market":"us","size":513983},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img21.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img21.jpg","type":"GRAPHIC","id":"NTFILEBx4mHUZQ4etz6dHx","market":"us","size":448365},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img22.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img22.jpg","type":"GRAPHIC","id":"NTFILE3rC1HE48mPihnt5z","market":"us","size":364644},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img23.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img23.jpg","type":"GRAPHIC","id":"NTFILE5LHcmDbUTDvzrV8w","market":"us","size":388876},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img24.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img24.jpg","type":"GRAPHIC","id":"NTFILEDiLp1TFjotuGpU5Q","market":"us","size":346629},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2img25.jpg","primary":false,"translateUrl":"","linkName":"tm262035d1_ex99-2img25.jpg","type":"GRAPHIC","id":"NTFILEDsA3Y4oYe5b3U7GS","market":"us","size":218386}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-06 13:00","pubTimestamp":1767675600,"title_zh":"Form 8-K - Current report","summary_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20594104","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465926000197-ALMS","pdf_url":"","pub_time":1767330000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926000197/0001104659-26-000197-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 8.01: Other Events","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"FORM 8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926000197/tm2534587d2_8k.htm","primary":true,"translateUrl":"","linkName":"tm2534587d2_8k.htm","type":"8-K","id":"NTFILEBBKEVfV4C6VGCERh","market":"us","size":28294}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-02 13:00","pubTimestamp":1767330000,"title_zh":"Form 8-K - Current report","summary_en":"Item 8.01: Other Events","summary_zh":"项目8.01：其他事项","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20406311","market":"us","labels":[],"media":"sec.gov","original_id":"AN184736725000050-ALMS","pdf_url":"","pub_time":1763010000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"ALMS","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/0001847367-25-000050-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/alms-20250930x10q.htm","primary":true,"translateUrl":"","linkName":"alms-20250930x10q.htm","type":"10-Q","id":"NTFILEBjfKGgCaRPyogsP6","market":"us","size":3152694},{"description":"EX-10.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/alms-20250930xex10d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250930xex10d1.htm","type":"EX-10.1","id":"NTFILEExvWcm75BiA8HyoX","market":"us","size":71423},{"description":"EX-31.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/alms-20250930xex31d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250930xex31d1.htm","type":"EX-31.1","id":"NTFILEAybUTsY5qdi2RbsH","market":"us","size":15388},{"description":"EX-31.2","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/alms-20250930xex31d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250930xex31d2.htm","type":"EX-31.2","id":"NTFILEuqPiumvYxYg9QdMq","market":"us","size":14892},{"description":"EX-32.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/alms-20250930xex32d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250930xex32d1.htm","type":"EX-32.1","id":"NTFILE4oXxMGcA6py9LTxs","market":"us","size":9683},{"description":"EX-32.2","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/alms-20250930xex32d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250930xex32d2.htm","type":"EX-32.2","id":"NTFILEBeEZ1qZ3Z2jkiC8z","market":"us","size":9106}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-11-13 13:00","pubTimestamp":1763010000,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20406099","market":"us","labels":[],"media":"sec.gov","original_id":"AN184736725000048-ALMS","pdf_url":"","pub_time":1763010000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/0001847367-25-000048-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm","primary":true,"translateUrl":"","linkName":"alms-20251113xex99d1.htm","type":"EX-99.1","id":"NTFILEAUTgKp5zJq7ioeT9","market":"us","size":185553},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113x8k.htm","primary":false,"translateUrl":"","linkName":"alms-20251113x8k.htm","type":"8-K","id":"NTFILE36NnhFgbNN8sd4hf","market":"us","size":32522},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1001.jpg","primary":false,"translateUrl":"","linkName":"alms-20251113xex99d1001.jpg","type":"GRAPHIC","id":"NTFILE6UaGLYtLDmfW7BYk","market":"us","size":4353}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-11-13 13:00","pubTimestamp":1763010000,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20122739","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925086612-ALMS","pdf_url":"","pub_time":1756872000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/0001104659-25-086612-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1.htm","primary":true,"translateUrl":"","linkName":"tm2525079d1_ex99-1.htm","type":"EX-99.1","id":"NTFILEBirUYuqD5tBTFFR8","market":"us","size":77436},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_8k.htm","primary":false,"translateUrl":"","linkName":"tm2525079d1_8k.htm","type":"8-K","id":"NTFILEGUBcNHrfWgiPUFZE","market":"us","size":25024},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img001.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img001.jpg","type":"GRAPHIC","id":"NTFILE2Z9ddjLFmQXLhL7w","market":"us","size":154171},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img002.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img002.jpg","type":"GRAPHIC","id":"NTFILEEq1gUmLodzd9i9TY","market":"us","size":319977},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img003.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img003.jpg","type":"GRAPHIC","id":"NTFILE39SGULdQnq9doseY","market":"us","size":176716},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img004.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img004.jpg","type":"GRAPHIC","id":"NTFILE9Bxy8ioM5qPrd9bt","market":"us","size":169699},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img005.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img005.jpg","type":"GRAPHIC","id":"NTFILEEqdxxGLuKR8nLNtQ","market":"us","size":143660},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img006.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img006.jpg","type":"GRAPHIC","id":"NTFILE2AfGzBpWsGDczYh7","market":"us","size":141574},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img007.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img007.jpg","type":"GRAPHIC","id":"NTFILE3hZLcRh97DYwynvf","market":"us","size":142731},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img008.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img008.jpg","type":"GRAPHIC","id":"NTFILE3ufXf3aC2LJiEeYg","market":"us","size":131929},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img009.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img009.jpg","type":"GRAPHIC","id":"NTFILEG8jfTEKPQKSzaFK7","market":"us","size":140837},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img010.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img010.jpg","type":"GRAPHIC","id":"NTFILE9pDhrgV2m2rN1E54","market":"us","size":142476},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img011.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img011.jpg","type":"GRAPHIC","id":"NTFILEAhgKnKQPbontTyVh","market":"us","size":123760},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img012.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img012.jpg","type":"GRAPHIC","id":"NTFILE6P39JiKJVEab1xaD","market":"us","size":148182},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img013.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img013.jpg","type":"GRAPHIC","id":"NTFILE51NMAHpTAD26nKfs","market":"us","size":131928},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img014.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img014.jpg","type":"GRAPHIC","id":"NTFILEA73m9xQPtyB2mYtw","market":"us","size":170360},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img015.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img015.jpg","type":"GRAPHIC","id":"NTFILE4YAyJBjehuVy1gV5","market":"us","size":117844},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img016.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img016.jpg","type":"GRAPHIC","id":"NTFILE9gTmYwCgvuM5Wwin","market":"us","size":175010},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img017.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img017.jpg","type":"GRAPHIC","id":"NTFILEHp2gLCdoXTjsCvek","market":"us","size":135199},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img018.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img018.jpg","type":"GRAPHIC","id":"NTFILEZETeXPFB5B3B3pKd","market":"us","size":155518},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img019.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img019.jpg","type":"GRAPHIC","id":"NTFILE56De2FRBVknFZ3QD","market":"us","size":192935},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img020.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img020.jpg","type":"GRAPHIC","id":"NTFILEFHCNVcN4BMbRLMg3","market":"us","size":145987},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img021.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img021.jpg","type":"GRAPHIC","id":"NTFILEDQGzcHAnz2GZDtAQ","market":"us","size":176522},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img022.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img022.jpg","type":"GRAPHIC","id":"NTFILEkqQ5CfVxFJ1uFhDp","market":"us","size":149343},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img023.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img023.jpg","type":"GRAPHIC","id":"NTFILE4owxZnq6Gr1Q1SNW","market":"us","size":113546},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img024.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img024.jpg","type":"GRAPHIC","id":"NTFILE7fhyWrr1ArxBDZM3","market":"us","size":160522},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img025.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img025.jpg","type":"GRAPHIC","id":"NTFILE5xZDZkaLbMSvVPzX","market":"us","size":180301},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img026.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img026.jpg","type":"GRAPHIC","id":"NTFILE4jJb82GKFzQxyPW7","market":"us","size":212919},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img027.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img027.jpg","type":"GRAPHIC","id":"NTFILE4e4PL9nXwQ4Rjnhg","market":"us","size":140591},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img028.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img028.jpg","type":"GRAPHIC","id":"NTFILEGaTqqofcBWni1EaB","market":"us","size":137023},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img029.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img029.jpg","type":"GRAPHIC","id":"NTFILEH574ftpZpMvvuPPs","market":"us","size":159355},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img030.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img030.jpg","type":"GRAPHIC","id":"NTFILE9wEjMEPPSyGT9r7h","market":"us","size":79737},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img031.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img031.jpg","type":"GRAPHIC","id":"NTFILEHHZMg9ajwKnGu24D","market":"us","size":145188},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img032.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img032.jpg","type":"GRAPHIC","id":"NTFILEABUFrVP8C7Gurbkz","market":"us","size":148319},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img033.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img033.jpg","type":"GRAPHIC","id":"NTFILE6sYG6rbajxFiYiXt","market":"us","size":141847},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img034.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img034.jpg","type":"GRAPHIC","id":"NTFILE3BhDtidejabTjnjd","market":"us","size":210243},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img035.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img035.jpg","type":"GRAPHIC","id":"NTFILE3qZcWmnBAwgqWk14","market":"us","size":157667},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img036.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img036.jpg","type":"GRAPHIC","id":"NTFILE3Rk63fVKe513nN8X","market":"us","size":136624},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img037.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img037.jpg","type":"GRAPHIC","id":"NTFILE6sKea7uZVFP5KbKn","market":"us","size":140323},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img038.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img038.jpg","type":"GRAPHIC","id":"NTFILE6SWxPYVvFZ4jeTj1","market":"us","size":145403},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img039.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img039.jpg","type":"GRAPHIC","id":"NTFILE2UqE8y3T7XS76BTv","market":"us","size":141366},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img040.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img040.jpg","type":"GRAPHIC","id":"NTFILEHbhdEYDZzi8aWDHD","market":"us","size":123753},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img041.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img041.jpg","type":"GRAPHIC","id":"NTFILEGhtFUmNriiJJwDWZ","market":"us","size":106707},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img042.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img042.jpg","type":"GRAPHIC","id":"NTFILE7MKo2G9aixa6aFoM","market":"us","size":145293},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img043.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img043.jpg","type":"GRAPHIC","id":"NTFILE9JnPiHkU943MhwEC","market":"us","size":139619},{"description":"GRAPHIC","seq":49,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img044.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img044.jpg","type":"GRAPHIC","id":"NTFILEAjJ9EUPr5bR8W3ki","market":"us","size":105639},{"description":"GRAPHIC","seq":50,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1img045.jpg","primary":false,"translateUrl":"","linkName":"tm2525079d1_ex99-1img045.jpg","type":"GRAPHIC","id":"NTFILE4kMHpbfd5RwHn7dL","market":"us","size":93102}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-09-03 12:00","pubTimestamp":1756872000,"title_zh":"Form 8-K - Current report","summary_en":"Item 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20180728","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925079224-ALMS","pdf_url":"","pub_time":1755288313000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"ALMS","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/0001104659-25-079224-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925079224/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILEBJTjbe8tmRvGtJz6","market":"us","size":7553}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2025-08-16 04:05","pubTimestamp":1755288313,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19982736","market":"us","labels":[],"media":"sec.gov","original_id":"AN184736725000041-ALMS","pdf_url":"","pub_time":1755057600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"ALMS","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000041/0001847367-25-000041-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000041/alms-20250630x10q.htm","primary":true,"translateUrl":"","linkName":"alms-20250630x10q.htm","type":"10-Q","id":"NTFILECQD8cnwq6T9UpdPM","market":"us","size":3058244},{"description":"EX-31.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000041/alms-20250630xex31d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250630xex31d1.htm","type":"EX-31.1","id":"NTFILE2UQY4sypwkfhxo1c","market":"us","size":15386},{"description":"EX-31.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000041/alms-20250630xex31d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250630xex31d2.htm","type":"EX-31.2","id":"NTFILEB6wsFFtcg6GmUeof","market":"us","size":14890},{"description":"EX-32.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000041/alms-20250630xex32d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250630xex32d1.htm","type":"EX-32.1","id":"NTFILEAz9fw3bewveZzSJm","market":"us","size":9676},{"description":"EX-32.2","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000041/alms-20250630xex32d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250630xex32d2.htm","type":"EX-32.2","id":"NTFILEHFMsjLLiTphS4cSL","market":"us","size":9099}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-08-13 12:00","pubTimestamp":1755057600,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19982728","market":"us","labels":[],"media":"sec.gov","original_id":"AN184736725000039-ALMS","pdf_url":"","pub_time":1755057600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/0001847367-25-000039-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm","primary":true,"translateUrl":"","linkName":"alms-20250813xex99d1.htm","type":"EX-99.1","id":"NTFILED7ioArVtpNiY4KJ6","market":"us","size":199295},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813x8k.htm","primary":false,"translateUrl":"","linkName":"alms-20250813x8k.htm","type":"8-K","id":"NTFILE7mx1GN892EjLc2Lo","market":"us","size":32889},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1001.jpg","primary":false,"translateUrl":"","linkName":"alms-20250813xex99d1001.jpg","type":"GRAPHIC","id":"NTFILE8otJr3CufmeoPCpX","market":"us","size":4353}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-08-13 12:00","pubTimestamp":1755057600,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目2.02：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19945092","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925073628-ALMS","pdf_url":"","pub_time":1754280000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925073628/0001104659-25-073628-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 5.07: Submission of Matters to a Vote of Security Holders","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"FORM 8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925073628/tm2521941d1_8k.htm","primary":true,"translateUrl":"","linkName":"tm2521941d1_8k.htm","type":"8-K","id":"NTFILEDd5qoRSDkeqbFQ3u","market":"us","size":30034}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-08-04 12:00","pubTimestamp":1754280000,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.07: Submission of Matters to a Vote of Security Holders","summary_zh":"项目5.07：将事项提交证券持有人表决","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19828364","market":"us","labels":[],"media":"sec.gov","original_id":"AN184736725000035-ALMS","pdf_url":"","pub_time":1751256000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K/A - Current report: [Amend]","symbol":"ALMS","title":"Form 8-K/A - Current report: [Amend]","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000035/0001847367-25-000035-index.htm","us_notice_code":"Form 8-K/A","us_title_en":"Form 8-K/A - Current report: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"8-K/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000035/alms-20250521x8ka.htm","primary":true,"translateUrl":"","linkName":"alms-20250521x8ka.htm","type":"8-K/A","id":"NTFILEA7JvjoxDpXRnznRm","market":"us","size":44089},{"description":"EX-23.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000035/alms-20250521xex23d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250521xex23d1.htm","type":"EX-23.1","id":"NTFILEAwejapDrKNKQEzRH","market":"us","size":2654},{"description":"EX-99.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000035/alms-20250521xex99d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250521xex99d1.htm","type":"EX-99.1","id":"NTFILEBEKjjBgjtdP2cBeG","market":"us","size":821419},{"description":"EX-99.2","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000035/alms-20250521xex99d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250521xex99d2.htm","type":"EX-99.2","id":"NTFILED1V3s4q743eNzUvy","market":"us","size":600061},{"description":"EX-99.3","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000035/alms-20250521xex99d3.htm","primary":false,"translateUrl":"","linkName":"alms-20250521xex99d3.htm","type":"EX-99.3","id":"NTFILE5WL8sR6rDWafW8Mr","market":"us","size":649029}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-06-30 12:00","pubTimestamp":1751256000,"title_zh":"Form 8-K/A - Current report: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19757515","market":"us","labels":[],"media":"sec.gov","original_id":"AN184736725000032-ALMS","pdf_url":"","pub_time":1749528000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-8 - Securities to be offered to employees in employee benefit plans","symbol":"ALMS","title":"Form S-8 - Securities to be offered to employees in employee benefit plans","titleType":"员工持股计划","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/0001847367-25-000032-index.htm","us_notice_code":"Form S-8","us_title_en":"Form S-8 - Securities to be offered to employees in employee benefit plans","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"S-8","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xs8.htm","primary":true,"translateUrl":"","linkName":"alms-20250610xs8.htm","type":"S-8","id":"NTFILE4tJcM6b5K3pzn787","market":"us","size":111863},{"description":"EX-5.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex5d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex5d1.htm","type":"EX-5.1","id":"NTFILEGvVEWZUxNaoJtimG","market":"us","size":16560},{"description":"EX-23.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex23d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex23d1.htm","type":"EX-23.1","id":"NTFILEjQzMnVwQuZF7vnJY","market":"us","size":2116},{"description":"EX-99.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex99d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex99d1.htm","type":"EX-99.1","id":"NTFILEDVh5Ariztx6mcZkj","market":"us","size":145040},{"description":"EX-99.2","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex99d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex99d2.htm","type":"EX-99.2","id":"NTFILEB9wyoDPHYkS93AW8","market":"us","size":447254},{"description":"EX-99.3","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex99d3.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex99d3.htm","type":"EX-99.3","id":"NTFILEAKAj2QF2M63WCKcY","market":"us","size":269765},{"description":"EX-99.4","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex99d4.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex99d4.htm","type":"EX-99.4","id":"NTFILE9t3mL5w4bs4TtbkM","market":"us","size":267758},{"description":"EX-99.5","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex99d5.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex99d5.htm","type":"EX-99.5","id":"NTFILEALYNzUHDrL5wkouv","market":"us","size":77259},{"description":"EX-99.6","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex99d6.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xex99d6.htm","type":"EX-99.6","id":"NTFILE6QncJkZj6Pn9NZLm","market":"us","size":52220},{"description":"EX-FILING FEES","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xexfees.htm","primary":false,"translateUrl":"","linkName":"alms-20250610xexfees.htm","type":"EX-FILING FEES","id":"NTFILEDyk7fbE6rEMkAPGg","market":"us","size":22253},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex5d1001.jpg","primary":false,"translateUrl":"","linkName":"alms-20250610xex5d1001.jpg","type":"GRAPHIC","id":"NTFILE3fFhZ5XtyttvzCMR","market":"us","size":6023},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex5d1002.gif","primary":false,"translateUrl":"","linkName":"alms-20250610xex5d1002.gif","type":"GRAPHIC","id":"NTFILE2P7RtDrk3Gmi6Rz6","market":"us","size":1108},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000032/alms-20250610xex99d2002.jpg","primary":false,"translateUrl":"","linkName":"alms-20250610xex99d2002.jpg","type":"GRAPHIC","id":"NTFILEC5Lx8t9vhfnJZj3n","market":"us","size":939}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Employee Stock Ownership","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"员工持股计划","pubTime":"2025-06-10 12:00","pubTimestamp":1749528000,"title_zh":"Form S-8 - Securities to be offered to employees in employee benefit plans","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19677746","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925051338-ALMS","pdf_url":"","pub_time":1747800000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925051338/0001104659-25-051338-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.01: Completion of Acquisition or Disposition of Assets;\nItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925051338/tm2515764d1_ex99-1.htm","primary":true,"translateUrl":"","linkName":"tm2515764d1_ex99-1.htm","type":"EX-99.1","id":"NTFILE6ugF4mLaasEgfiF8","market":"us","size":9325},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925051338/tm2515764d1_8k.htm","primary":false,"translateUrl":"","linkName":"tm2515764d1_8k.htm","type":"8-K","id":"NTFILE65oPyaJqERxdnnsg","market":"us","size":42537}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-05-21 12:00","pubTimestamp":1747800000,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.01: Completion of Acquisition or Disposition of Assets;\nItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.01项：资产收购或处置完成；第5.02项：董事或某些高级职员的离职；选举董事；若干人员的委任：若干人员的补偿安排；项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19667859","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925050436-ALMS","pdf_url":"","pub_time":1747685121000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"ALMS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1847367/0001104659-25-050436-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 5.07: Submission of Matters to a Vote of Security Holders","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"FORM 8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925050436/tm2515049d1_8k.htm","primary":true,"translateUrl":"","linkName":"tm2515049d1_8k.htm","type":"8-K","id":"NTFILE3h9g9bYFzW6RuCR8","market":"us","size":38809}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-05-20 04:05","pubTimestamp":1747685121,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.07: Submission of Matters to a Vote of Security Holders","summary_zh":"项目5.07：将事项提交证券持有人表决","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19645019","market":"us","labels":[],"media":"sec.gov","original_id":"AN184736725000028-ALMS","pdf_url":"","pub_time":1747254723000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"ALMS","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1847367/0001847367-25-000028-index.html","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331x10q.htm","primary":true,"translateUrl":"","linkName":"alms-20250331x10q.htm","type":"10-Q","id":"NTFILEFZQuefuG88KZMm7G","market":"us","size":2234225},{"description":"EX-31.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331xex31d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250331xex31d1.htm","type":"EX-31.1","id":"NTFILE4dNceeqBybvacUcC","market":"us","size":15384},{"description":"EX-31.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331xex31d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250331xex31d2.htm","type":"EX-31.2","id":"NTFILEBuAU4FrQWQ55Lfvv","market":"us","size":14888},{"description":"EX-32.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331xex32d1.htm","primary":false,"translateUrl":"","linkName":"alms-20250331xex32d1.htm","type":"EX-32.1","id":"NTFILEFFAgbG7Xm3CU2KDs","market":"us","size":9675},{"description":"EX-32.2","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331xex32d2.htm","primary":false,"translateUrl":"","linkName":"alms-20250331xex32d2.htm","type":"EX-32.2","id":"NTFILE91MmSqQVJAFnercQ","market":"us","size":9098}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-05-15 04:32","pubTimestamp":1747254723,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":1.5379},{"period":"1month","weight":0.8355},{"period":"3month","weight":3.5551},{"period":"6month","weight":5.1308},{"period":"1year","weight":2.0129},{"period":"ytd","weight":1.1609}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alumis Inc.于2021年1月29日注册成立，为特拉华州公司。他们是一家临床阶段的生物制药公司，最初专注于开发两种酪氨酸激酶2（TYK2）抑制剂：ESK-001，一种他们正在开发的第二代抑制剂，以实现最大的靶向抑制，以及A-005，一种中枢神经系统渗透分子。该公司的使命是通过靶向治疗取代广泛的免疫抑制，显著改善患者的生活。","exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"aProfile":null}}}